Shuailin Li

Nov 19, 2024 | nature.com | Andrew White |Shuailin Li |Nacho Aguilo |Carlos Martin |Carlos Martín |Helen McShane | +3 more

AbstractThe only currently licensed vaccine against tuberculosis (TB), Bacille Calmette Guérin (BCG), is insufficient to control the epidemic. MTBVAC is a live attenuated strain of Mycobacterium tuberculosis (M.tb) and is one the most advanced TB vaccine candidates in the pipeline. It is more efficacious than BCG in preclinical models including non-human primates (NHPs), and has demonstrated safety and immunogenicity in human populations.